MADRID Dec. 20 () –
Novo Nordisk shares fell as much as 29.2% on the Copenhagen Stock Exchange this Friday after the Danish laboratory reported the results of a trial for CagriSema, the new experimental drug to fight obesity that combines semaglutide, component of ‘Ozempic’ and ‘Wegovy’, with cagrilintide.
However, by surpassing the mid-session, the shares of the Danish pharmaceutical company managed to partially offset their losses to limit the fall to around 19%, thus completely erasing the gains of the Novo Nordisk share in 2024, which would now lose around a 14% so far this year.
In a statement, Novo Nordisk reported the main results of REDEFINE 1, a 68-week efficacy and safety trial with CagriSema that included 3,417 randomized people who were obese or overweight with one or more comorbidities and a body weight initial average of 106.9 kg.
In this sense, the laboratory has highlighted that the trial achieved its primary endpoint by demonstrating superior and statistically significant weight loss at week 68 with CagriSema compared to placebo.
“People treated with CagriSema achieved a weight loss of over 22.7% after 68 weeks,” the company said, adding that 40.4% of patients who received CagriSema achieved a weight loss of 25%. or more after 68 weeks.
“We are encouraged by the weight loss profile of CagriSema,” said Martin Holst Lange, Executive Vice President of Development at Novo Nordisk, adding that this was achieved “despite only 57% of patients reaching the highest dose of CagriSema.” CagriSema”.
“With the insights gained from the REDEFINE 1 trial, we plan to further explore the additional weight loss potential of CagriSema,” he added.
In this sense, the pharmaceutical company has indicated that the results of the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and obesity or overweight are expected during the first half of 2025.
Add Comment